Stay updated with breaking news from Single Ascending Dose Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AlzeCure gets late-breaking abstract on NeuroRestore ACD856 clinical data accepted to AD/PD 2022 conferenceAlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Al...
STOCKHOLM, SWEDEN / ACCESSWIRE / January 18, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule
Late breaker will show ADUHELM effect on plasma pTau181 reduction, and its correlation with amyloid beta and slowing cognitive and functional decline.Additional phase 3b late breaker data will shed light